Inclacumab

Synonyms: Anti-Human selectin P Recombinant Antibody
Inclacumab(抗人 P-选择素重组抗体)是一种人源 IgG4 单克隆抗体,可选择性靶向 P-选择素,Kd 值为 9.9 nM,并通过抑制 P-选择素糖蛋白配体 1 (PSGL-1) 模拟肽与 P-选择素结合(IC50 值为 1.9 μg/mL)而强烈抑制细胞黏附。
产品编号: MS-N83813 纯度: 99.80% CAS No.: 1256258-86-2
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价

产品描述

Inclacumab(抗人 P-选择素重组抗体)是一种人源 IgG4 单克隆抗体,可选择性靶向 P-选择素,Kd 值为 9.9 nM,并通过抑制 P-选择素糖蛋白配体 1 (PSGL-1) 模拟肽与 P-选择素结合(IC50 值为 1.9 μg/mL)而强烈抑制细胞黏附。

生物实验数据

生物活性 Inclacumab (Anti-Human selectin P Recombinant Antibody) is a human IgG4 monoclonal antibody that selectively targets P-selectin with a Kd of 9.9 nM and strongly inhibits cell adhesion by blocking the binding of P-selectin glycoprotein ligand 1 (PSGL-1) mimetic peptide to P-selectin with an IC50 of 1.9 μg/mL.
IC50 & Target PSGL-1-positive cell adhesion to P-selectin:430 ng/mL, P-selectin:9.9 nM (Kd), PSGL-1 mimetic peptide binding to P-selectin:1.9 μg/mL, TRAP-induced platelet-leukocyte aggregation:1.4 μg/mL
体外研究
(In Vitro)

Inclacumab (0.4-40 μg/mL; 5 min) significantly reduces flow adhesion of P-Selectin with Whole Blood (WB) and isolated White Blood Cell (I-WBC) and shows a more stronger effect on isolated white cells.
Inclacumab shows great binding affinity to P-selectin with a Kd value of 9.9 nM.
Inclacumab inhibits PSGL-1 mimetic peptide binding with P-selectin with an IC50 value of 1.9 μg/mL.
Inclacumab blocks the adhesion of PSGL-1 expressing cells to an immobilized P-selectin with an IC50 value of 430 ng/mL.
Inclacumab (0-100 μg/mL; 5min) dose-dependently inhibits thrombin receptor-activating peptide (TRAP)-induced platelet-leukocyte aggregates (PLA) levels with an IC50 value of 1.4 μg/mL.

体内研究
(In Vivo)

Inclacumab (4 mg/kg; s.c. once) reduces TRAP- and ADP-induced PLA levels in cynomolgus monkeys.
Inclacumab (2-50 mg/kg; i.v.; once a week for 13 weeks) inhibits TRAP induced PLA levels in cynomolgus monkeys.

Animal Model: Cynomolgus monkeys
Dosage: 4 mg/kg
Administration: Subcutaneous injection; 4 mg/kg; once
Result: Significantly reduced TRAP-induced PLA levels from 25% to 6% and supressed PLA formation ≥80% for at least 28 days post treatment. Remained plasma concentrations >20 μg/mL during post treatment for 28 days. Significantly inhibited the formation of ADP (10 μM)-induced PLAs.
Animal Model: Cynomolgus monkeys
Dosage: 2, 10, and 50 mg/kg
Administration: Intravenous injection; once daily; for 13 weeks
Result: Inhibited TRAP-induced PLA and remained concentrations at all three dose levels are higher than 20 μg/mL. Persisted the full inhibition of PLA formation between dosing period.
Clinical Trial
NCT NumberSponsorConditionStart DatePhase
NCT01815827Hoffmann-La Roche
Healthy Volunteer
2013-06PHASE1
NCT04935879Pfizer
Sickle Cell Disease|Vaso-occlusive Pain Episode in Sickle Cell Disease|Vaso-occlusive Crisis
2021-10-04PHASE3
NCT05348915Pfizer
Sickle Cell Disease|Vaso-occlusive Crisis|Vaso-occlusive Pain Episode in Sickle Cell Disease
2022-03-29PHASE3
性状 液体
颜色 Colorless to light yellow

化学信息

CAS No. 1256258-86-2
别名 Anti-Human selectin P Recombinant Antibody

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Shipping with dry ice.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础